Intravitreal Bevacizumab (Avastin) in Treatment of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy

Authors

  • Attaullah Shah Bukhari
  • Aijaz Ahmed Shah
  • Shahid Jamal Siddiqui

Keywords:

Bevacizumab intravitreal injection, Vitreous hemorrhage, Proliferative Diabetic Retinopathy.

Abstract

OBJECTIVE: To evaluate the role of intravitreal bevacizumab (Avastin) in treatment of vitreous hemorrhage due to proliferative diabetic retinopathy.
METHODS: This quasi-experimental trial was conducted at department of Ophthalmology Khairpur Medical College, Khairpur Mir’s from January 2016 to June 2016. A number of 30 eyes of 30 patients having vitreous hemorrhage were selected and given intravitreal injection of bevacizumab 1.25 mg/0.05ml. Main outcome improvement in visual acuity with Snellen chart was observed at one week, four week and three months.
RESULTS: Among 30 eyes visual acuity improved in 4 eyes (13.33%) in 1st week, 24 eyes 80%, improve within four weeks, at the end of 3 months 25(83.33%) eyes improve in visual acuity, while 5 eyes (16.66%) developed recurrent vitreous hemorrhage.
CONCLUSION: In our study the Intravitreal bevacizumab produced partial or complete resolution of vitreous hemorrhage due to Proliferative Diabetic Retinopathy. Which is more useful in recent onset of hemorrhage. It is my suggestion that it can be a fine alternative of surgery.

Downloads

Published

15-04-2019

How to Cite

1.
Bukhari AS, Shah AA, Siddiqui SJ. Intravitreal Bevacizumab (Avastin) in Treatment of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy. J Liaq Uni Med Health Sci [Internet]. 2019 Apr. 15 [cited 2024 Nov. 15];17(02):76-9. Available from: http://121.52.154.205/index.php/jlumhs/article/view/86

Issue

Vol. 17 No. 02 (2018): Journal Of Liaquat University of Medical & Health Sciences

Section

Original Articles

License

Submission of a manuscript to the journal implies that all authors have read and agreed to the content of the undertaking form or the Terms and Conditions.

When an article is accepted for publication, the author(s) retain the copyright and are required to grant the publisher the right of first publication and other non-exclusive publishing rights to JLUMHS.

Articles published in the Journal of Liaquat University of Medical & health sciences are open access articles under a Creative Commons Attribution-Noncommercial - Share Alike 4.0 License. This license permits use, distribution and reproduction in any medium; provided the original work is properly cited and initial publication in this journal. This is in accordance with the BOAI definition of open access. In addition to that users are allowed to remix, tweak and build upon the work non-commercially as long as appropriate credit is given and the new creations are licensed under the identical terms. Or, in certain cases it can be stated that all articles and content there in are published under creative commons license unless stated otherwise.